BLTE (Belite Bio) FCF Yield % : -1.53 (As of Dec. 13, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Belite Bio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Belite Bio's Trailing 12-Month Free Cash Flow is $-29.90 Mil, and Market Cap is $1,956.82 Mil. Therefore, Belite Bio's FCF Yield % for today is -1.53%.

The historical rank and industry rank for Belite Bio's FCF Yield % or its related term are showing as below:

BLTE' s FCF Yield % Range Over the Past 10 Years
Min: -3.24 Med: 0 Max: 0
Current: -1.53

BLTE's FCF Yield % is ranked better than
78.83% of 1507 companies
in the Biotechnology industry
Industry Median: -13.02 vs BLTE: -1.53

Belite Bio's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

Belite Bio FCF Yield % Historical Data

The historical data trend for Belite Bio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belite Bio FCF Yield % Chart

Belite Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-1.58

-2.24

Belite Bio Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Yield %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Belite Bio's FCF Yield %

For the Biotechnology subindustry, Belite Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Belite Bio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Belite Bio's FCF Yield % falls into.

Belite Bio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Belite Bio's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-29.9	/	1333.58505
	=	-2.24%

Belite Bio's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/	1447.621584
	=	0.00%

Belite Bio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Belite Bio FCF Yield % Related Terms

Thank you for viewing the detailed overview of Belite Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Belite Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Belite Bio Inc (NAS:BLTE) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130

Website

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.